Nevertheless, previous research by us and others demonstrated that MEHD7945A, a dual mAb targeting EGFR and HER3, is only partially able to overcome cetuximab resistance in HNSCC cell lines (De Pauw et al., 2017; Fayette et al., 2016). The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.